Equillium, Inc. Hits New 52-Week High of $2.62, Up 249%

Equillium, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 2.62 on March 13, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 249.22%, significantly outpacing the S&P 500's performance of 20.12% during the same period. Despite being a loss-making entity, Equillium's market capitalization stands at USD 106 million, reflecting its position within the microcap category. The company currently has a price-to-book ratio of 3.42, indicating how the market values its equity relative to its book value. Additionally, Equillium's debt-to-equity ratio is reported at -1.06, and its return on equity is at -78.92%, highlighting the financial dynamics at play. As Equillium continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high underscores the stock's notable activity and performance trends over the past year.